| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ... The lancet oncology 17 (11), 1497-1508, 2016 | 1497 | 2016 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1435 | 2022 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1303 | 2018 |
| The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... Cancer discovery 4 (6), 662-673, 2014 | 921 | 2014 |
| Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ... Cancer cell 33 (5), 853-861. e4, 2018 | 837 | 2018 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 802 | 2014 |
| MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met … MM Awad, GR Oxnard, DM Jackman, DO Savukoski, D Hall, P Shivdasani, ... Journal of clinical oncology 34 (7), 721-730, 2016 | 696 | 2016 |
| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 652 | 2021 |
| ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013 | 652 | 2013 |
| Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA) PW Sperduto, TJ Yang, K Beal, H Pan, PD Brown, A Bangdiwala, ... JAMA oncology 3 (6), 827-831, 2017 | 650 | 2017 |
| First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992-1000, 2019 | 554 | 2019 |
| STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment S Koyama, EA Akbay, YY Li, AR Aref, F Skoulidis, GS Herter-Sprie, ... Cancer research 76 (5), 999-1008, 2016 | 539 | 2016 |
| Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ... Journal of Clinical Oncology 38 (21), 2369-2379, 2020 | 536 | 2020 |
| Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ... Nature genetics 50 (9), 1271-1281, 2018 | 516 | 2018 |
| Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial CA Shu, JF Gainor, MM Awad, C Chiuzan, CM Grigg, A Pabani, ... The Lancet Oncology 21 (6), 786-795, 2020 | 515 | 2020 |
| PD-1 inhibitor–related pneumonitis in advanced cancer patients: radiographic patterns and clinical course M Nishino, NH Ramaiya, MM Awad, LM Sholl, JA Maattala, M Taibi, ... Clinical Cancer Research 22 (24), 6051-6060, 2016 | 476 | 2016 |
| A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan, A Naing, ... Cell 183 (2), 347-362. e24, 2020 | 466 | 2020 |
| Acquired resistance to crizotinib from a mutation in CD74–ROS1 MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ... New England Journal of Medicine 368 (25), 2395-2401, 2013 | 464 | 2013 |
| Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients G De Velasco, Y Je, D Bossé, MM Awad, PA Ott, RB Moreira, F Schutz, ... Cancer immunology research 5 (4), 312-318, 2017 | 439 | 2017 |
| False-positive plasma genotyping due to clonal hematopoiesis Y Hu, BC Ulrich, J Supplee, Y Kuang, PH Lizotte, NB Feeney, NM Guibert, ... Clinical Cancer Research 24 (18), 4437-4443, 2018 | 391 | 2018 |
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute在 dfci.harvard.edu 的电子邮件经过验证
